Table 3.
Adjusted* hazard ratio (95% confidence interval) for mortality, by estimated GFR category
| Estimated glomerular filtration rate (mL/min/1.73 m2) | ||||
|---|---|---|---|---|
| 45–74 | 30–44 | 15–29 | <15 | |
|
Studies with Albumin:Creatinine Ratio
| ||||
| British Columbia | Reference | 1.40 (1.20, 1.62) | 3.06 (2.66, 3.52) | 4.07 (3.42, 4.84) |
| CRIB | Reference | 1.18 (0.14, 9.65) | 1.93 (0.24, 15.32) | 3.39 (0.43, 26.88) |
| MASTERPLAN | Reference | 1.32 (0.54, 3.20) | 2.62 (1.11, 6.21) | 4.49 (1.08, 18.66) |
| RENAAL | Reference | 1.13 (0.84, 1.50) | 1.95 (1.43, 2.66) | - |
| Steno | Reference | 1.46 (0.80, 2.68) | 2.78 (1.48, 5.19) | 5.90 (2.33, 14.96) |
|
| ||||
|
Studies with Protein:Creatinine Ratio
| ||||
| AASK | Reference | 1.66 (1.25, 2.20) | 1.55 (1.10, 2.19) | 6.28 (0.85, 46.44) |
| MDRD | Reference | 1.75 (1.10, 2.77) | 1.79 (1.13, 2.85) | 1.68 (0.79, 3.57) |
|
| ||||
|
Studies with Dipstick Proteinuria
| ||||
| Kaiser Permanente Northwest | Reference | 1.24 (1.05, 1.47) | 2.41 (1.94, 2.99) | - |
|
| ||||
| OVERALL | Reference | 1.35 (1.23, 1.49) | 2.25 (1.81, 2.79) | 3.74 (2.69, 5.20) |
*
Adjusted for age, sex, race, prior cardiovascular disease, smoking status, diabetes mellitus, systolic blood pressure, and serum total cholesterol concentration.
AASK: African American Study of Kidney Disease and Hypertension; CRIB: Chronic Renal Impairment in Birmingham; MASTERPLAN: Multifactorial Approach and Superior Treatment Efficacy in Renal Patients with the Aid of a Nurse Practicioner; MDRD: Modification of Diet in Renal Disease; RENAAL: Reduction of Endpoints in Non-insulin Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan; Steno: Steno Type 1 Diabetes Study